Amgen pays $50M to option Cytokinetics' HF drug

25 May 2009

US biotechnology major Amgen has agreed to pay Cytokinetics a non-refundable exercise fee of $50.0 million to license heart failure  drug candidate CK-1827452 and related compounds. The agent was developed  as part of a 2006 collaboration between the two US firms.

"After reviewing the data from the CK-1827452 clinical trials, we are  excited about the opportunity to advance this molecule," said Amgen  executive vice president for R&D, Roger Perlmutter.

The agent - a myosin muscle activator - has a novel mechanism of action,  Dr Perlmutter added. Shares in Cytokinetics jumped 44% to $3 in  premarket trading on the day of the news, May 26.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory

Companies featured in this story

More ones to watch >